MESO
Mesoblast limited.

5,294
Mkt Cap
$2.17B
Volume
326,301.00
52W High
$21.50
52W Low
$9.61
PE Ratio
-19.90
MESO Fundamentals
Price
$16.83
Prev Close
$17.45
Open
$17.10
50D MA
$17.43
Beta
1.40
Avg. Volume
224,921.36
EPS (Annual)
-$0.8443
P/B
3.61
Rev/Employee
$211,960.04
Loading...
Loading...
News
all
press releases
FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain
Mesoblast says FDA feedback supports filing plans for its cell therapy to treat chronic back pain, showing reduced pain and lower opioid use in a late-stage trial.read more...
Benzinga·12h ago
News Placeholder
More News
News Placeholder
Mesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?
Mesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell...
MarketBeat·8d ago
News Placeholder
Mesoblast Chair Jane Bell To Retire; Appoints Philip Facchina As Non-executive Chair
(RTTNews) - Mesoblast Limited (MESO, MSB.AX) announced that Jane Bell will retire from her role as Chair and will remain on the Board as a non-executive director. The Board has unanimously appointed...
Nasdaq News: Markets·19d ago
News Placeholder
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy PR Newswire VANCOUVER, BC, Dec. 16, 2025 Issued on behalf of Avant...
PR Newswire·1mo ago
News Placeholder
Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?
Mesoblast (NASDAQ:MESO) Shares Gap Up - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Mesoblast (NASDAQ:MESO) Stock Price Passes Below 50-Day Moving Average - Here's Why
Mesoblast (NASDAQ:MESO) Shares Pass Below 50-Day Moving Average - What's Next...
MarketBeat·2mo ago
News Placeholder
Mesoblast (NASDAQ:MESO) Shares Gap Up - Here's Why
Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next...
MarketBeat·2mo ago
News Placeholder
Mesoblast Appoints James M O'Brien New CFO
(RTTNews) - Mesoblast Ltd. (MESO, MSB.AX), an Australian regenerative medicine company, Monday announced the appointment of James M O'Brien as its US-based Chief Financial Officer or CFO. The company...
Nasdaq News: Markets·2mo ago
News Placeholder
Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·2mo ago
News Placeholder
All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
<
1
2
...
>

Latest MESO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.